Shanghai Kaibao Pharmaceutical Cash Flow-to-Debt Ratio
Shanghai Kaibao Pharmaceutical cash flow-to-debt ratio. Shanghai Kaibao Pharmaceutical (300039) has a Cash Flow-to-Debt Ratio of 0.46x as of September 2025, meaning its operating cash flow of CN¥190.98 Million could theoretically repay 0% of its total liabilities (CN¥412.55 Million) in one year. Check 300039 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Shanghai Kaibao Pharmaceutical (2006–2025)
Cash flow-to-debt ratio of Shanghai Kaibao Pharmaceutical from 2006 to 2025. Historical debt coverage capacity for Shanghai Kaibao Pharmaceutical across 20 annual periods. Check Shanghai Kaibao Pharmaceutical (300039) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Shanghai Kaibao Pharmaceutical Cash Flow-to-Debt Ratio by Year (2006–2025)
Shanghai Kaibao Pharmaceutical cash flow-to-debt ratio by year from 2006 to 2025. Year-by-year debt coverage analysis for Shanghai Kaibao Pharmaceutical. For the full cash flow conversion analysis, see cash efficiency ratio of Shanghai Kaibao Pharmaceutical.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.64x | CN¥230.74 Million | CN¥359.64 Million | ▼ -4.4% |
| 2024 | 0.67x | CN¥278.95 Million | CN¥415.45 Million | ▼ -4.1% |
| 2023 | 0.70x | CN¥382.66 Million | CN¥546.82 Million | ▼ -7.4% |
| 2022 | 0.76x | CN¥376.42 Million | CN¥498.24 Million | ▲ +86.3% |
| 2021 | 0.41x | CN¥126.08 Million | CN¥310.90 Million | ▼ -51.6% |
| 2020 | 0.84x | CN¥250.65 Million | CN¥298.96 Million | ▼ -31.5% |
| 2019 | 1.22x | CN¥334.09 Million | CN¥273.01 Million | ▲ +22.3% |
| 2018 | 1.00x | CN¥262.36 Million | CN¥262.26 Million | ▲ +27.9% |
| 2017 | 0.78x | CN¥245.76 Million | CN¥314.26 Million | ▼ -18.6% |
| 2016 | 0.96x | CN¥314.88 Million | CN¥327.61 Million | ▲ +23.8% |
| 2015 | 0.78x | CN¥327.08 Million | CN¥421.16 Million | ▼ -36.0% |
| 2014 | 1.21x | CN¥282.38 Million | CN¥232.72 Million | ▼ -26.0% |
| 2013 | 1.64x | CN¥270.23 Million | CN¥164.72 Million | ▼ -4.1% |
| 2012 | 1.71x | CN¥243.32 Million | CN¥142.29 Million | ▲ +105.2% |
| 2011 | 0.83x | CN¥98.31 Million | CN¥117.97 Million | ▲ +461.7% |
| 2010 | 0.15x | CN¥19.79 Million | CN¥133.39 Million | ▼ -44.0% |
| 2009 | 0.26x | CN¥52.74 Million | CN¥199.20 Million | ▲ +45.8% |
| 2008 | 0.18x | CN¥18.70 Million | CN¥102.95 Million | ▼ -33.9% |
| 2007 | 0.27x | CN¥23.27 Million | CN¥84.64 Million | ▲ +0.2% |
| 2006 | 0.27x | CN¥19.70 Million | CN¥71.80 Million | — |